Clinical Trial Update: Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating thalidomide for hereditary hemorrhagic telangiectasia has completed, assessing its efficacy in reducing epistaxis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Hemorrhagic Telangiectasia

Drugs mentioned

• Thalidomide (thalidomide)

Snippet

Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia | Conditions: Hereditary Hemorrhagic Telangiectasia, Epistaxis | Phase 2 | Status: COMPLETED